Fisher Asset Management LLC Cuts Stake in Edwards Lifesciences Corporation $EW

Fisher Asset Management LLC cut its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 21.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 247,420 shares of the medical research company’s stock after selling 68,972 shares during the period. Fisher Asset Management LLC’s holdings in Edwards Lifesciences were worth $19,242,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its stake in Edwards Lifesciences by 7.0% in the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company’s stock worth $10,719,000 after purchasing an additional 9,069 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Edwards Lifesciences by 13.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company’s stock valued at $6,706,000 after purchasing an additional 10,078 shares in the last quarter. Arkadios Wealth Advisors purchased a new position in shares of Edwards Lifesciences in the second quarter worth $300,000. Atlantic Union Bankshares Corp lifted its stake in shares of Edwards Lifesciences by 2,240.9% during the third quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company’s stock worth $925,000 after buying an additional 11,384 shares during the period. Finally, OMERS ADMINISTRATION Corp grew its holdings in shares of Edwards Lifesciences by 97.3% during the second quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock valued at $3,481,000 after buying an additional 21,950 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

EW has been the subject of a number of research analyst reports. Citigroup restated a “buy” rating and issued a $101.00 target price (up from $96.00) on shares of Edwards Lifesciences in a research note on Thursday, December 11th. UBS Group restated a “neutral” rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Piper Sandler reiterated an “overweight” rating and issued a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Stifel Nicolaus set a $110.00 price target on shares of Edwards Lifesciences and gave the stock a “buy” rating in a report on Tuesday, January 20th. Finally, Evercore restated an “outperform” rating and set a $94.00 price objective on shares of Edwards Lifesciences in a research note on Monday, January 5th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus target price of $96.14.

Edwards Lifesciences Trading Down 0.1%

Shares of NYSE:EW opened at $85.23 on Thursday. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89. The business has a 50 day moving average of $82.71 and a two-hundred day moving average of $81.41. The company has a market capitalization of $49.50 billion, a PE ratio of 46.57, a PEG ratio of 2.22 and a beta of 0.93.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.54 billion. During the same period last year, the firm earned $0.59 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Activity at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,700 shares of the company’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total value of $650,419.00. Following the completion of the transaction, the chief financial officer owned 39,898 shares of the company’s stock, valued at approximately $3,370,184.06. This represents a 16.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 24,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total value of $2,012,160.00. Following the completion of the sale, the vice president directly owned 21,266 shares in the company, valued at approximately $1,782,941.44. The trade was a 53.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 79,144 shares of company stock worth $6,685,688 in the last 90 days. Corporate insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.